Why Annexon (ANNX) Stock Is Getting Hammered
Portfolio Pulse from Henry Khederian
Annexon Inc (ANNX) shares dropped by 57.16% after announcing topline results from its ARCHER Phase 2 trial of ANX007 in patients with geographic atrophy (GA). The drug was generally well-tolerated, with three cases of endophthalmitis found to be administration-related.
May 25, 2023 | 3:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Annexon Inc's stock price dropped by 57.16% after announcing topline results from its ARCHER Phase 2 trial of ANX007 in patients with geographic atrophy.
The stock price of Annexon Inc (ANNX) dropped significantly after the company announced topline results from its ARCHER Phase 2 trial of ANX007 in patients with geographic atrophy. Although the drug was generally well-tolerated, the market reacted negatively to the news, causing the stock price to drop by 57.16%. This indicates that investors may have concerns about the drug's potential and the company's future prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100